Association of clinical parameters or gene expression with colorectal cancer patient survival
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| Cohort | Variable | HR (95% CI) | p Value (log-rank) | HR (95% CI) | p Value (wald) |
| TCGA | Age (<median vs >median) | 1.02 (0.37 to 2.83) | 0.9614 | ||
| Gender (male vs female) | 1.32 (0.49 to 3.55) | 0.579 | |||
| Tumour location (left vs right) | 0.92 (0.32 to 2.68) | 0.8846 | |||
| Tumour stage (III–IV vs I–II) | 7.87 (1.77 to 35.07) | 0.0014* | 8.37 (1.82 to 38.51) | 0.0063* | |
| Microsatellite status (MSS vs MSI) | 2.896 (0.66 to 12.75) | 0.1597 | |||
| miR-224 (high vs low) | 2.99 (1.08 to 8.23) | 0.0259* | 2.88 (0.97 to 8.56) | 0.0571 | |
| Italian set 1 | Age (<median vs >median) | 0.81 (0.39 to 1.71) | 0.5817 | ||
| Gender (male vs female) | 1.56 (0.72 to 3.39) | 0.2598 | |||
| Tumour location (left vs right) | 0.74 (0.35 to 1.57) | 0.4284 | |||
| Tumour stage (III–IV vs I–II) | 2.85 (1.28 to 6.35) | 0.0073 | 2.44 (1.09 to 5.48) | 0.0302* | |
| MSI status (MSS vs MSI) | 2.04 (0.87 to 4.81) | 0.0951 | |||
| miR-224 (high vs low) | 3.32 (1.15 to 9.59) | 0.0137 | 2.77 (0.95 to 8.105) | 0.063 | |
| Italian set 2 | Age (<median vs >median) | 0.74 (0.32 to 1.69) | 0.4757 | ||
| Gender (male vs female) | 2.2 (0.9 to 5.36) | 0.0744 | |||
| Tumour location (left vs right) | 1.68 (0.73 to 3.83) | 0.2148 | |||
| Tumour stage (III–IV vs I–II) | 4.04 (1.7 to 9.57) | 0.0006* | 3.89 (1.63 to 9.26) | 0.0022* | |
| miR-224 (high vs low) | 4.41 (1.03 to 18.84) | 0.0207* | 4.14 (0.96 to 17.76) | 0.056 | |
| Romania | Age (<median vs >median) | 1.16 (0.42 to 3.2) | 0.7733 | ||
| Gender (male vs female) | 2.44 (0.69 to 8.66) | 0.154 | |||
| Tumour location (left vs right) | 1.3 (0.44 to 3.9) | 0.633 | |||
| Tumour stage (III–IV vs I–II) | 9.33 (2.1 to 41.54) | 0.0004* | 7.47 (1.52 to 36.65) | 0.0132* | |
| miR-224 (high vs low) | 4.25 (1.01 to 18.89) | 0.0331* | 1.76 (0.36 to 8.64) | 0.4831 | |
| Austria | Age (<median vs >median) | 0.88 (0.51 to 1.49) | 0.6239 | ||
| Gender (male vs female) | 0.82 (0.48 to 1.43) | 0.4909 | |||
| Tumour location (left vs right) | 0.62 (0.36 to 1.06) | 0.0802 | |||
| Tumour Stage (III–IV vs II) | 2.89 (1.02 to 8.15) | 0.037* | 3.41 (1.18 to 9.83) | 0.023* | |
| miR-224 (high vs low) | 2.14 (1.21 to 3.77) | 0.0059* | 2.36 (1.32 to 4.21) | 0.0037* | |
| UK (overall survival) | Age (<median vs >median) | 1.15 (0.31 to 4.3) | 0.8322 | ||
| Gender (male vs female) | 0.8 (0.21 to 2.98) | 0.7399 | |||
| Tumour location (left vs right) | 0.98 (0.24 to 3.92) | 0.9781 | |||
| Tumour stage (III–IV vs I–II) | 2.7 (0.68 to 10.83) | 0.1428 | |||
| miR-224 (high vs low) | 4.92 (1.31 to 18.46) | 0.0181* | |||
| UK (metastasis-free survival) | Age (<median vs >median) | 1.54 (0.5 to 4.72) | 0.446 | ||
| Gender (male vs female) | 0.75 (0.25 to 2.24) | 0.6074 | |||
| Tumour location (left vs right) | 0.6 (0.16 to 2.18) | 0.4326 | |||
| Tumour stage (III–IV vs I–II) | 2.92 (0.93 to 9.21) | 0.0558 | |||
| miR-224 (high vs low) | 6.51 (1.97 to 21.51) | 0.0008* | |||
*Statistically significant with p<0.05.
MSI, microsatellite instability; MSS, microsatellite stable; TCGA, The Cancer Genome Atlas.